ATE30380T1 - Pharmazeutische formulierungen mit mehrfachen einheiten. - Google Patents

Pharmazeutische formulierungen mit mehrfachen einheiten.

Info

Publication number
ATE30380T1
ATE30380T1 AT82306170T AT82306170T ATE30380T1 AT E30380 T1 ATE30380 T1 AT E30380T1 AT 82306170 T AT82306170 T AT 82306170T AT 82306170 T AT82306170 T AT 82306170T AT E30380 T1 ATE30380 T1 AT E30380T1
Authority
AT
Austria
Prior art keywords
coating
cores
active substance
substance
sup
Prior art date
Application number
AT82306170T
Other languages
English (en)
Inventor
Helle Bechgaard
Peter Houmoeller
Original Assignee
Benzon As Alfred
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benzon As Alfred filed Critical Benzon As Alfred
Application granted granted Critical
Publication of ATE30380T1 publication Critical patent/ATE30380T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT82306170T 1981-11-20 1982-11-19 Pharmazeutische formulierungen mit mehrfachen einheiten. ATE30380T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK516481A DK150008C (da) 1981-11-20 1981-11-20 Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
EP82306170A EP0080341B1 (de) 1981-11-20 1982-11-19 Pharmazeutische Formulierungen mit mehrfachen Einheiten

Publications (1)

Publication Number Publication Date
ATE30380T1 true ATE30380T1 (de) 1987-11-15

Family

ID=8140030

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82306170T ATE30380T1 (de) 1981-11-20 1982-11-19 Pharmazeutische formulierungen mit mehrfachen einheiten.

Country Status (12)

Country Link
US (1) US4606909A (de)
EP (1) EP0080341B1 (de)
JP (1) JPS5892610A (de)
AT (1) ATE30380T1 (de)
AU (1) AU563725B2 (de)
CA (1) CA1198370A (de)
DE (2) DE80341T1 (de)
DK (1) DK150008C (de)
FI (1) FI79943C (de)
NO (1) NO823891L (de)
NZ (1) NZ202565A (de)
ZA (1) ZA828433B (de)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
JPH0653658B2 (ja) * 1984-12-17 1994-07-20 中外製薬株式会社 安定な錠剤の製造法
EP0187703B1 (de) * 1985-01-11 1992-08-05 Teijin Limited Präparate mit verzögerter Freisetzung
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
US4912146A (en) * 1985-01-30 1990-03-27 Warner-Lambert Company Coated dosage forms
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
LU85943A1 (fr) * 1985-06-12 1987-01-13 Galephar Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
CH666405A5 (de) * 1985-06-24 1988-07-29 Ciba Geigy Ag Feste, haltbare darreichungsformen mit elastischem filmueberzug.
EP0212745B1 (de) * 1985-08-16 1991-04-10 The Procter & Gamble Company Partikel mit konstanter Wirkstofffreisetzung
DE3678643D1 (de) * 1985-08-16 1991-05-16 Procter & Gamble Partikel mit konstanter wirkstofffreisetzung.
DE3678644D1 (de) * 1985-08-16 1991-05-16 Procter & Gamble Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung.
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
LU86077A1 (fr) * 1985-09-18 1987-04-02 Pharlyse Sa Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
CH669523A5 (de) * 1986-06-25 1989-03-31 Mepha Ag
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
CA1324083C (en) * 1987-03-09 1993-11-09 Tetsu Miyoshi Pharmaceutical preparations containing non-steroidal anti-inflammatory agents
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4837211A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Spironolactone composition
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
GB8805695D0 (en) * 1988-03-10 1988-04-07 Nycomed As Enteric coated spheroidal granules
FI101344B1 (fi) † 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
NZ230763A (en) * 1988-09-27 1991-10-25 Takeda Chemical Industries Ltd Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
JPH082781B2 (ja) * 1988-10-18 1996-01-17 嘉明 川島 中空顆粒状医薬及びその製法
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
DE3920082A1 (de) * 1989-06-20 1991-03-07 Roehm Gmbh Filmbildendes waessriges ueberzugsmittel fuer feste arzneimittel, verfahren zu seiner herstellung und verwendung
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
DE69033861T2 (de) * 1989-08-30 2002-06-06 Kynoch Agrochemicals (Proprietary) Ltd., Sandton Herstellung eines Dosierungsmittels
US5130140A (en) * 1989-09-14 1992-07-14 Hoeschst-Roussel Pharmaceuticals Inc. Method of making direct dry compressible acetaminophen composition
US5198228A (en) * 1989-09-14 1993-03-30 Hoechst-Roussel Pharmaceuticals Inc. Direct dry compressible acetaminophen tablet
US5037658A (en) * 1989-09-14 1991-08-06 Hoechst-Roussel Pharmaceuticals, Inc. Direct dry compressible acetaminophen composition
ES2064564T3 (es) * 1989-09-21 1995-02-01 American Cyanamid Co Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
IL96311A (en) † 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
GB9104854D0 (en) * 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
KR100297541B1 (ko) * 1992-12-13 2001-11-26 마티에우 디올라이티 방출제어형약학적제형의제조방법및이방법에의해제조된약학적제형
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
CA2164344C (en) * 1993-08-30 2004-06-29 Stanley Lech Tablet coating based on a melt-spun mixture of a saccharide and a polymer
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ATE190487T1 (de) * 1993-10-27 2000-04-15 Daiichi Seiyaku Co Granuläre zubereitung
PT758244E (pt) 1994-05-06 2002-04-29 Pfizer Formas de dosagem libertacao controlada de azitromicina
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ATE206044T1 (de) * 1994-07-08 2001-10-15 Astrazeneca Ab Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
EP0951278A2 (de) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Minitablette formulierung zur verzögerte freigabe von cisapride
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
ID23503A (id) 1997-07-01 2000-04-27 Pfizer Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina
DK1007024T3 (da) * 1997-07-01 2003-11-17 Pfizer Prod Inc Doseringsformer af sertralin med forsinket frigivelse
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
IT1296980B1 (it) 1997-12-17 1999-08-03 Istituto Pirri S R L Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19820529A1 (de) 1998-05-08 1999-11-11 Lohmann Therapie Syst Lts Wirkstoff enthaltende orale und mucosale Zubereitung mit steuerbarer Wirkstofffreisetzung und ihre Verwendung
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
EP1404323B1 (de) * 2001-06-05 2009-10-28 The University of Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
EP1435922A1 (de) * 2001-10-15 2004-07-14 Röhm GmbH & Co. KG Verwendung eines copolymeren zur herstellung einer arzneiform, die als wirkstoff ein peptid oder protein enthält
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
BRPI0409125A (pt) * 2003-04-08 2006-03-28 Progenics Pharm Inc terapia de combinação para constipação compreendendo um laxativo e um antagonista de opióide periférico
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1689368B1 (de) 2003-12-04 2016-09-28 Bend Research, Inc Sprüherstarrungsverfahren mit einem extruder zur herstellung von multiteilchenförmigen kristallinen arzneimittelzusammensetzungen
ES2308274T3 (es) 2003-12-04 2008-12-01 Pfizer Products Inc. Procedimiento para fabricar multiparticulados farmaceuticos.
CA2547597A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
BRPI0419032B8 (pt) 2004-09-09 2021-05-25 Psicofarma S A De C V composição farmacêutica de liberação prolongada de hidralazina
WO2006046256A1 (en) * 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP2008520736A (ja) 2004-11-23 2008-06-19 アマダス ファーマシューティカルズ インコーポレイテッド 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法
EP2623099A1 (de) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen
CN101137378A (zh) * 2005-01-20 2008-03-05 普罗热尼奇制药公司 甲基纳曲酮和相关化合物治疗术后胃肠功能障碍的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
EP1874282B1 (de) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1912629A4 (de) * 2005-07-08 2012-09-12 Univ Arkansas Asymmetrisch beschichtete tablette
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AU2007254215A1 (en) * 2006-05-19 2007-11-29 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of viral infections
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
US7713549B2 (en) * 2006-06-30 2010-05-11 Board Of Trustees Of The University Of Arkansas Extended release perforated tablet
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
CN101621931A (zh) 2006-11-27 2010-01-06 H.隆德贝克有限公司 杂芳基酰胺衍生物
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
EP3263571B2 (de) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Kristallform von (r)-n-methylnaltrexonebromide und verwendungen davon
EP2203056A1 (de) * 2007-09-25 2010-07-07 Nirmal Mulye Pharmazeutische formulierungen mit protrahierter wirkstofffreigabe
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2009265034B2 (en) 2008-07-01 2015-09-03 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
UA106231C2 (uk) 2009-04-24 2014-08-11 Айсьютика Пти Лтд Разова доза фармацевтичної композиції індометацину (варіанти)
CA2776173A1 (en) 2009-09-30 2011-04-07 Nicholas Marini Cofactors and methods of use for individuals
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
RU2017129378A (ru) 2011-07-15 2019-02-04 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
US20140341984A1 (en) * 2011-09-16 2014-11-20 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
EP2945616B1 (de) 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Behandlung von lungenerkrankungen
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CN106456997B (zh) 2014-02-27 2018-12-28 纽斯尔特科学公司 用于减少或预防肝性脂肪变性的组合物和方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
EP3206491B1 (de) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Verwendung von methylnaltrexon zur verringerung der tumorprogression
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
MX2020002078A (es) 2017-08-24 2020-09-21 Adamas Pharma Llc Composiciones de amantadina, preparaciones de estas y métodos de uso.
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN111166729A (zh) * 2020-03-19 2020-05-19 珠海赛隆药业股份有限公司 一种口服的替加环素肠溶微球及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
FR1503582A (fr) * 1966-07-18 1967-12-01 Sedaph Soc D Applic Pharma Sa Procédé de préparation d'une nouvelle forme solide de médicament
FR2059978A1 (en) * 1969-08-20 1971-06-11 Sogeras Enteric coating of sensitive medicaments inp
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
AU5949773A (en) * 1972-08-30 1975-02-27 Univ Illinois Tge virus vaccine
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US4291016A (en) * 1976-07-27 1981-09-22 Sandoz Ltd. Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
IT1115596B (it) * 1978-03-13 1986-02-03 Bayer Italia Spa Metodo per la preparazione di microgranuli gastoresistenti ed enterosolubili di sostanze farmaceutiche,in particolare di sostanze proteiche e microgranuli preparati con detto metodo
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
FR2447192A1 (fr) * 1979-01-25 1980-08-22 Adria Lab Inc Forme galenique a liberation prolongee d'indoprofene
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap

Also Published As

Publication number Publication date
EP0080341B1 (de) 1987-10-28
DK150008B (da) 1986-11-17
DE80341T1 (de) 1983-10-27
FI79943C (fi) 1990-04-10
EP0080341A2 (de) 1983-06-01
US4606909A (en) 1986-08-19
EP0080341A3 (en) 1983-09-14
AU563725B2 (en) 1987-07-23
DK150008C (da) 1987-05-25
FI79943B (fi) 1989-12-29
DK516481A (da) 1983-05-21
FI823975L (fi) 1983-05-21
JPH0478611B2 (de) 1992-12-11
NO823891L (no) 1983-05-24
DE3277520D1 (en) 1987-12-03
AU9072282A (en) 1983-05-26
ZA828433B (en) 1983-08-31
FI823975A0 (fi) 1982-11-19
CA1198370A (en) 1985-12-24
NZ202565A (en) 1987-03-06
JPS5892610A (ja) 1983-06-02

Similar Documents

Publication Publication Date Title
ATE30380T1 (de) Pharmazeutische formulierungen mit mehrfachen einheiten.
EP0524180B1 (de) Verfahren zum geschmacksabdecken von ibuprofen
PL323362A1 (en) Method of treating inflammatory inteestine diseases using oral preparations of polyunsaturated omega-3 acids
JPS63174922A (ja) 有効成分の投与のための医薬製剤
FI833099A0 (fi) Farmaceutiska blandningar som ges oralt
SE8602722L (sv) Hallbara administreringsformer
KR890009376A (ko) 분무 건조된 이부프로펜
DK0765157T3 (da) Pellets
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
JPH0157090B2 (de)
AU623731B2 (en) Water dispersible gemfibrozil compositions
EP1004297B1 (de) Pharmazeutische Zusammensetzungen zur oralen Verabreichung, die einen magensaftresistenten Überzug auf der Basis von Acrylatpolymeren enthalten
WO1989008448A1 (en) Enteric coated spheroidal granules
KR0171413B1 (ko) 젬피브로질 제제
IE902554A1 (en) Aspirin granules with gastroprotectant coating
JPS54126722A (en) Slow release antibiotic tablet
EP0094117A2 (de) Therapeutische Granulate